Hudson Edge Investment Partners’s Pacira BioSciences PCRX Stock Holding History

Hudson Edge Investment Partners’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,304	Closed	-$229K	–	147
2022 Q3	$229K	Sell	4,304 -5,796	-57%	-$322K	0.09%	145
2022 Q2	$589K	Sell	10,100 -132	-1%	-$8.65K	0.21%	90
2022 Q1	$781K	Buy	10,232 +464	+5%	+$30.9K	0.25%	71
2021 Q4	$588K	Sell	9,768 -6,129	-39%	-$338K	0.18%	106
2021 Q3	$890K	Hold	15,897	–	–	0.29%	76
2021 Q2	$965K	Buy	15,897 +3,518	+28%	+$223K	0.31%	74
2021 Q1	$868K	Buy	12,379 +452	+4%	+$32.3K	0.29%	66
2020 Q4	$714K	Buy	11,927 +5,637	+90%	+$330K	0.25%	75
2020 Q3	$378K	Buy	+6,290	New	+$365K	0.15%	125

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Hudson Edge Investment Partners's PCRX Position: Q4 2022 in Review

Hudson Edge Investment Partners sold out of Pacira BioSciences (PCRX) in Q4 2022, closing a stake of 4,304 shares — an estimated $229K sold.

Hudson Edge Investment Partners first reported a position in PCRX in Q3 2020 and held it in 9 quarters. The position peaked at $965K in Q2 2021. 273 funds tracked by Wall St. Rank hold PCRX as of Q4 2022.

Hudson Edge Investment Partners reported no remaining Pacira BioSciences position as of Q4 2022 after selling out during the quarter.
Hudson Edge Investment Partners sold 4,304 Pacira BioSciences shares in Q4 2022, an estimated $229K.
Hudson Edge Investment Partners first reported a position in Pacira BioSciences in Q3 2020 and held it in 9 quarters.
Hudson Edge Investment Partners's Pacira BioSciences position peaked at $965K in Q2 2021.
273 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2022.

Based on Hudson Edge Investment Partners's 13F filing for Q4 2022, filed 14 Feb 2023.